CEN Biotech, Inc. CENBF
OTC PK
| 09/30/2022 | 06/30/2022 | 03/31/2022 | 12/31/2021 | 09/30/2021 | |
|---|---|---|---|---|---|
| Revenue | 404.56% | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 404.56% | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 404.56% | -- | -- | -- | -- |
| SG&A Expenses | -85.06% | -- | -- | -- | -- |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -85.06% | -- | -- | -- | -- |
| Operating Income | 92.62% | -- | -- | -- | -- |
| Income Before Tax | -235.28% | -- | -- | -- | -- |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -233.69% | -- | -- | -- | -- |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -233.69% | -- | -- | -- | -- |
| EBIT | 92.62% | -- | -- | -- | -- |
| EBITDA | 94.92% | -- | -- | -- | -- |
| EPS Basic | -120.55% | -- | -- | -- | -- |
| Normalized Basic EPS | 94.20% | -- | -- | -- | -- |
| EPS Diluted | -194.12% | -- | -- | -- | -- |
| Normalized Diluted EPS | 93.78% | -- | -- | -- | -- |
| Average Basic Shares Outstanding | 54.87% | -- | -- | -- | -- |
| Average Diluted Shares Outstanding | 34.33% | -- | -- | -- | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |